Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 2
Submit an article Journal homepage
152
Views
10
CrossRef citations to date
0
Altmetric
Review

Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?

Nathan WD Lamond Department of Medicine of Dalhousie University, Queen Elizabeth II Health Sciences Centre, 457 Bethune Building, 1278 Tower Road, Halifax, NS, B3H 2Y9, Canada.
,
Chris Skedgel Atlantic Clinical Cancer Research Unit (ACCRU), Queen Elizabeth II Health Sciences Centre, 242 Centre for Clinical Research, 5790 University Avenue, Halifax, NS, B3H 1V7, Canada
&
Tallal Younis Department of Medicine of Dalhousie University, Queen Elizabeth II Health Sciences Centre, 454 Bethune Building, 1278 Tower Road, Halifax, NS, B3H 2Y9, Canada. [email protected]
Pages 243-250 | Published online: 09 Jan 2014

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011).
  • Broekx S, Den Hond E, Torfs R et al. The costs of breast cancer prior to and following diagnosis. Eur. J. Health Econ. 12(4), 311–317 (2011).
  • Burstein HJ, Prestrud AA, Seidenfeld J et al.; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28(23), 3784–3796 (2010).
  • Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22(8), 1736–1747 (2011).
  • Carlson RW, Allred DC, Anderson BO et al.; NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 7(2), 122–192 (2009).
  • Fisher B, Jeong JH, Bryant J et al.; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364(9437), 858–868 (2004).
  • Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res. 9(6), R81 (2007).
  • Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817–2826 (2004).
  • van ‘t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530–536 (2002).
  • Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6), 607–616 (2004).
  • Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320(8), 479–484 (1989).
  • Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726–3734 (2006).
  • Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl Cancer Inst. 89(22), 1673–1682 (1997).
  • Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
  • Paik S, Shak S, Tang G et al. Risk classification of breast cancer patients by the recurrence score assay: comparison to guidelines based on patient age, tumor size, and tumor grade. Presented at: The 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–12 December 2004.
  • Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23(12), 2716–2725 (2005).
  • Bryant J. Oncotype Dx correlates more closely with prognosis than Adjuvant Online. Presented at: 9th International Conference on Primary Therapy of Early Breast Cancer. St Gallen, Switzerland, 26–29 January 2005.
  • Mamounas EP, Tang G, Fisher B et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J. Clin. Oncol. 28(10), 1677–1683 (2010).
  • Chang JC, Makris A, Gutierrez MC et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res. Treat. 108(2), 233–240 (2008).
  • Toi M, Iwata H, Yamanaka T et al.; Japan Breast Cancer Research Group-Translational Research Group. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116(13), 3112–3118 (2010).
  • Lo SS, Mumby PB, Norton J et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J. Clin. Oncol. 28(10), 1671–1676 (2010).
  • Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4), 381–387 (2010).
  • Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX®) in estrogen receptor positive (ER+) node negative (pN0) Breast Cancer in Academic Canadian Centers. Presented at: 2012 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2012.
  • Gligorov J, Pivot XB, Naman HL et al. Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early stage breast cancer in France. Presented at: 2012 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2012.
  • Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J. Oncol. Pract. 3(4), 182–186 (2007).
  • Asad J, Jacobson AF, Estabrook A et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am. J. Surg. 196(4), 527–529 (2008).
  • Kamal AH, Loprinzi CL, Reynolds C et al. How well do standard prognostic criteria predict Oncotype DX scores? J. Clin. Oncol. 25, Abstract 18S 576 (2007).
  • Hassett MJ, Silver SM, Hughes ME et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J. Clin. Oncol. 30(18), 2218–2226 (2012).
  • Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol. 4(5), 603–610 (2008).
  • Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am. J. Manag. Care 11(5), 313–324 (2005).
  • Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109(6), 1011–1018 (2007).
  • Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res. Treat. 112(1), 175–187 (2008).
  • Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost–effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 15(5), 457–465 (2010).
  • Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res. Treat. 127(3), 739–749 (2011).
  • Hornberger J, Chien R, Krebs K, Hochheiser L. US insurance program’s experience with a multigene assay for early-stage breast cancer. J. Oncol. Pract. 7(3S), e38–e45 (2012).
  • Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost–utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res. Treat. 133(3), 1115–1123 (2012).
  • Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest. 27(10), 953–959 (2009).
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
  • Snow S, Rayson D, Barnes PJ, Sellon M, Thompson K, Younis T. Does Her2/neu status affect adjuvant chemotherapy utilization? A population based analysis. Presented at: American Society of Clinical Oncology Breast Cancer Symposium. Washington DC, USA, 5–7 September 2008.
  • Albain KS, Barlow WE, Shak S et al.; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11(1), 55–65 (2010).
  • Gonzalez-Angulo AM, Barlow WE, Gralow J et al. SWOG S1007: a Phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. Presented at: 2011 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4–8 June 2012.
  • Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J. Natl Cancer Inst. 104(1), 56–66 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.